AVROBIO, Inc. Forecasted to Post Q2 2023 Earnings of $1.35 Per Share (NASDAQ:AVRO)

Posted by on May 25th, 2023

AVROBIO, Inc. (NASDAQ:AVRO – Get Rating) – Wedbush lifted their Q2 2023 earnings per share (EPS) estimates for shares of AVROBIO in a report released on Monday, May 22nd. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $1.35 per share for the quarter, up from their prior forecast of ($0.16). The consensus estimate for AVROBIO’s current full-year earnings is ($1.77) per share. Wedbush also issued estimates for AVROBIO’s Q3 2023 earnings at ($0.57) EPS, Q4 2023 earnings at ($0.57) EPS, FY2023 earnings at ($0.35) EPS, Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.27) EPS, Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($1.26) EPS, FY2025 earnings at ($0.98) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.74) EPS.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of AVROBIO in a research report on Friday, March 24th.

AVROBIO Price Performance

AVRO opened at $1.26 on Thursday. The business has a fifty day moving average of $0.92 and a 200 day moving average of $0.98. AVROBIO has a 52-week low of $0.56 and a 52-week high of $1.93. The company has a quick ratio of 5.40, a current ratio of 5.40 and a debt-to-equity ratio of 0.29. The stock has a market cap of $55.57 million, a P/E ratio of -0.55 and a beta of 1.59.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Bailard Inc. raised its position in shares of AVROBIO by 76.4% in the 1st quarter. Bailard Inc. now owns 45,492 shares of the company’s stock worth $45,000 after acquiring an additional 19,700 shares in the last quarter. Atlas Venture Life Science Advisors LLC raised its position in shares of AVROBIO by 0.5% in the 1st quarter. Atlas Venture Life Science Advisors LLC now owns 4,541,381 shares of the company’s stock worth $4,541,000 after acquiring an additional 20,518 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of AVROBIO in the 1st quarter worth $26,000. BNP Paribas Arbitrage SA raised its position in shares of AVROBIO by 931.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 32,108 shares of the company’s stock worth $30,000 after acquiring an additional 28,995 shares in the last quarter. Finally, Mirabella Financial Services LLP purchased a new position in AVROBIO during the 1st quarter worth $42,000. 55.74% of the stock is owned by institutional investors.

AVROBIO Company Profile

(Get Rating)

Avrobio, Inc engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm’s clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis.

Featured Stories

Earnings History and Estimates for AVROBIO (NASDAQ:AVRO)

Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.